Shaping the next generation of novel treatments.

Apogee Therapeutics is the first company to be formed around assets discovered by and licensed from Paragon. Established in 2022, Apogee is advancing a pipeline of potentially best-in-class product candidates targeting clinically validated biology and well-established development pathways to address the needs of the millions of people living with immunological and inflammatory disorders.

Spyre Therapeutics is the second company to be formed around assets discovered by and licensed from Paragon. Established in 2023, Spyre is advancing a pipeline of product candidates that maximize the efficacy, safety, and convenience of treatments for inflammatory bowel disease (IBD), combining best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to potentially transform the treatment paradigm.

Oruka Therapeutics is the third company to be formed around assets discovered by and licensed from Paragon. Established in 2024, Oruka is advancing a pipeline of potentially best-in-class biologics that aim to redefine the standard of care for patients with chronic skin diseases, including plaque psoriasis.

Jade Biosciences is the fourth company to be formed around assets discovered by and licensed from Paragon. Jade is developing a pipeline of potentially best-in-class therapies to redefine the standard of care for patients living with autoimmune conditions.

Crescent Biopharma is the fifth company to be formed around assets discovered by and licensed from Paragon. Crescent is advancing a pipeline of precision-engineered molecules designed to advance care for patients with solid tumors.